Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

Abstract Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer (EOC) that is associated with elevated interleukin-6 (IL-6) expression, resistance to chemotherapy, and increased mortality. Although bevacizumab (Bev) is a widely used anti-angiogenic agent for EOC, the efficacy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, Misato Saito, Junya Tabata, Ryo Yokomizo, Daito Noguchi, Takafumi Kuroda, Ayako Kawabata, Jiro Suzuki, Kazuaki Takahashi, Haruka Matsuzawa, Misayo Miyake, Masataka Takenaka, Yasushi Iida, Satoshi Yanagida, Aikou Okamoto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4e5e333a9dd74977baf25b7ae087534a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

Ejemplares similares